Drug Trial Radar · NCT07446153
A Clinical Study of HRS-8364 in the Treatment of Advanced Solid Tumor Subjects
Last checked: Nov 20, 2026Latest source record: Apr 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
282
Planned (sponsor's estimate)
Start
Mar 19, 2026
Primary completion
Dec 2028
Study completion Dec 2029
Sponsor
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 3, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is an open, multicenter, Phase I/II clinical trial, divided into three stages: dose escalation, dose expansion and efficacy expansion.
Conditions
- Solid Tumor
Interventions
HRS-8364 TabletDrug
HRS-8364 tablet.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Dose-Limiting Toxicity (DLT)Time frame: Post-dose at Day 1 to Day 21.
- The Maximum Tolerated Dose (MTD)Time frame: Post-dose at Day 1 to the end of treatment visit, about 1 year.
- Recommended dosage for Phase II (RP2D)Time frame: Post-dose at Day 1 to the end of treatment visit, about 1 year.
- Incidence and severity of adverse events (AEs)Time frame: From signing the informed consent form to safety follow-up completed, about 1 year.
- Objective Response Rate (ORR)Time frame: From the first administration to the end of treatment visit, about 1 year.
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
The Sixth Affiliated Hospital, Sun-Yat-Sen University
Guangzhou, Guangdong, China · Recruiting
Liaoning Cancer Hospital & Institute
Shenyang, Liaoning, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.